Researchers have significantly advanced its development of a new solution for cardiac amyloidosis, leveraging Attruby. Preliminary trial results suggests significant improvements for those affected from this severe illness. This emphasis highlights BridgeBio's focus to treating critical patient needs in the cardiology arena. Attruby: BridgeBio's N